Pigmented villonodular synovitis of the ankle in an adolescent

Kaneko, Koichi; Nakahara, Daishi; Tobe, Masaru; H, Iwase; Inoué, Yoshihiro; Ohbayashi, Osamu; Kurosawa, Hisashi

doi:10.1007/s002640000141

Cited by 16 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Involvement of the foot and ankle occurs in fewer than 10% of patients with PVNS, and the clinical behavior and treatment are not well described. 3,4,5,6,11 This paper presents, to our knowledge, the largest series and longest followup of PVNS of the foot and ankle. We report 11 patients with PVNS of the foot and ankle treated at one institution.…”

Section: Introductionmentioning

confidence: 90%

Pigmented Villonodular Synovitis of the Foot and Ankle

Brien¹,

Sacoman²,

Mirra³

2004

Foot Ankle Int.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 90%

Pigmented Villonodular Synovitis of the Foot and Ankle

Brien¹,

Sacoman²,

Mirra³

2004

Foot Ankle Int.

View full text Add to dashboard Cite

show abstract

“…The disease, which can involve all synovial-lined structures, particularly the knee joint, is characterized by proliferation of synovial tissues and invasion of cartilage and bone around the joints. PVNS causes clinical swelling and pain, and the diffuse form or recurrence can trigger rapid articular cartilage damage associated with severe functional impairment, eventually leading to joint replacement or even amputation (11)(12)(13)(14). Although surgical synovectomy, either via open surgery or arthroscopy, is considered the standard treatment for PVNS (7,15), post-operative complications and limitations, including longer hospitalization and rehabilitation periods, post-operative stiffness, and in particular, high rates of recurrence are common.…”

Section: Introductionmentioning

confidence: 99%

Imatinib mesylate induces mitochondria-dependent apoptosis and inhibits invasion of human pigmented villonodular synovitis fibroblast-like synovial cells

et al. 2015

View full text Add to dashboard Cite

Pigmented villonodular synovitis (PVNS) is a rare sarcoma-like disorder characterized by synovial lesions proliferation and invasion to articular cartilage for which no effective treatments are available. Imatinib mesylate (IM) is known to exert antitumor activity in some tumors, but its effects on PVNS fibroblast-like synoviocytes (PVNS-FLS) and the specific mechanism involved remain to be established. In the present study, the in vitro effects of IM on cell proliferation and survival rates were investigated in PVNS-FLS. Apoptosis induction was assessed via acridine orange/ethidium bromide (AO)/(EB) and Annexin V/PI staining as well as western blotting. The invasion ability of PVNS-FLS was evaluated by Transwell invasion chambers. IM significantly inhibited survival and invasion ability of PVNS-FLS in a dose- and time-dependent manner. The drug-treated cell groups exhibited markedly higher apoptosis, which was blocked upon pretreatment with the specific caspase-9 inhibitor Z-LEHD-FMK. Expression of cleaved caspase-9 was significantly increased and the Bcl-2 family and caspase-3 were activated following treatment with IM. Our results collectively demonstrated that IM has a strong antiproliferative effect on PVNS-FLS in vitro, attributable to induction of mitochondrial-dependent apoptosis in association with activation of caspase-9/-3 and the Bcl-2/Bax family, and exhibits significant inhibition on the invasion ability of PVNS-FLS, suggesting that IM may be useful as a novel treatment of this disease.

show abstract

“…The history may or may not include an episode of trauma. The clinical presentation may be a subtle swollen enlargement of a periarticular region, while a frank tumorlike mass may be found impinging on joint structures (3,5,6,16,18,29,30,39,42,51,61,(64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77).…”

Section: Epidemiologymentioning

confidence: 99%